Man Group’s Biocept, Inc. BIOC Stock Holding History

Man Group’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-553	Closed	-$74K	–	2046
2020 Q4	$74K	Buy	+553	New	+$78.8K	﹤0.01%	1789

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $434M AUM 19.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group's BIOC Position: Q1 2021 in Review

Man Group sold out of Biocept, Inc. (BIOC) in Q1 2021, closing a stake of 553 shares — an estimated $74K sold.

Man Group first reported a position in BIOC in Q4 2020 and held it in 1 quarter. The position peaked at $74K in Q4 2020. 22 funds tracked by Wall St. Rank hold BIOC as of Q1 2021.

Man Group reported no remaining Biocept, Inc. position as of Q1 2021 after selling out during the quarter.
Man Group sold 553 Biocept, Inc. shares in Q1 2021, an estimated $74K.
Man Group first reported a position in Biocept, Inc. in Q4 2020 and held it in 1 quarter.
Man Group's Biocept, Inc. position peaked at $74K in Q4 2020.
22 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2021.

Based on Man Group's 13F filing for Q1 2021, filed 17 May 2021.